


Participant Flow: enrolment age – 1 to 3 years (12 to 36 months)



Baseline characteristics of participants (Oral ranitidine group) - at enrolment

Serial no. of patients	Age (months)	Gender	Weight (kg)	MUAC [†] (cm)	Height (cm)	Pulse rate [‡]	Temp. (°C)	Resp. rate [§]	Dehydration
1.	36	Male	15	16	96	102	37.2	30	Nil
2.	33	Male	14	16	100	106	37.2	32	Nil
3.	12	Male	10.5	14.5	80	108	36.8	36	Nil
4.	20	Female	11	16	98	104	36.7	32	Nil
5.	35	Male	13.5	15	90.5	98	36.8	24	Nil
6.	26	Male	14	15	88	110	37	28	Nil
7.	16	Female	10	15	84	102	36.9	30	Nil
8.	36	Male	13	14.5	89	104	36.8	28	Nil
9.	20	Male	13	15	88	102	37.1	36	Nil
10.	15	Female	10	14	86	98	36.8	28	Nil
11.	16	Male	10	14	86	102	36.5	36	Nil
12.	24	Female	13	15	89	104	36.9	34	Nil
13.	12	Female	10	16	83	106	37.3	32	Nil
14.	19	Male	11	15.5	85	102	36.6	34	Nil
15.	36	Male	18	16	94	96	36.9	30	Nil
16.	34	Male	21	16	106	98	36.7	28	Nil
17.	36	Male	15	16	98	104	37.2	32	Nil
18.	26	Female	13	15	104	94	36.8	30	Nil
19.	14	Female	12	16	84	106	37.3	36	Nil
20.	12	Male	10	14.5	86	102	36.9	34	Nil

[†]MUAC, mid upper arm circumference. [‡]in beats/minute. [§]in breaths/minute

Baseline characteristics of participants (probiotic group) – at enrolment

Serial no. of patients	Age (months)	Gender	Weight (kg)	MUAC [†] (cm)	Height (cm)	Pulse rate [‡]	Temp. (°C)	Resp. rate [§]	Dehydration
1.	15	Male	12	15	87	108	37.1	36	Nil
2.	12	Female	10.5	14	84	102	36.9	34	Nil
3.	36	Male	14	16	95	98	36.6	28	Nil
4.	18	Female	11	16	89	104	37.2	34	Nil
5.	13	Male	10	14.5	80	108	36.8	36	Nil
6.	12	Male	10	15	85	106	36.5	32	Nil
7.	24	Female	13	16	90	102	36.8	30	Nil
8.	11	Male	10	14	84	106	36.7	32	Nil
9.	16	Female	12	16	86	104	36.6	34	Nil
10.	20	Male	11.5	14.5	83	102	37	32	Nil

[†]MUAC, mid upper arm circumference. [‡]in beats/minute. [§]in breaths/minute

Baseline characteristics of participants (placebo -vitamin C) group – at enrolment

Serial no. of patients	Age (months)	Gender	Weight (kg)	MUAC[†] (cm)	Height (cm)	Pulse rate[‡]	Temp. (°C)	Resp. rate[§]	Dehydration
1.	12	Female	10.5	15	84	104	36.9	34	Nil
2.	20	Female	11	14	85	104	37.3	36	Nil
3.	13	Male	11.5	16	88	102	36.6	34	Nil
4.	15	Female	12	15.5	86	106	37.3	34	Nil
5.	24	Male	14	16	89	100	37.1	36	Nil
6.	14	Male	12	16	83	108	36.8	34	Nil
7.	19	Female	16	16	84	104	36.5	36	Nil
8.	19	Female	20	17.5	85	102	36.6	32	Nil
9.	23	Female	14	16	89	102	36.8	34	Nil
10.	18	Male	12	15	84	106	37.3	36	Nil

[†]MUAC, mid upper arm circumference. [‡]in beats/minute. [§]in breaths/minute

Study outcome measures (primary) - oral ranitidine group

Serial no. of patients	Pre-treatment stool consistency/frequency	Stool consistency/frequency[†]	Post-treatment stool consistency/frequency[‡]
1.	Loose/6 per day	Formed/2 per day	Formed/1 per day
2.	Loose/10 per day	Formed/1 per day	Formed/1 per day
3.	Loose/5 per day	Formed/1 per day	Formed/1 per day
4.	Loose/4 per day	Formed/1 per day	Formed/1 per day
5.	Loose/5 per day	Formed/1 per day	Formed/1 per day
6.	Loose/5 per day	Formed/1 per day	Formed/2 per day
7.	Loose/4 per day	Formed/1 per day	Formed/1 per day
8.	Loose/3 per day	Formed/1 per day	Formed/1 per day
9.	Loose/4 per day	Formed/2 per day	Formed/1 per day
10.	Loose/4 per day	Formed/1 per day	Formed/1 per day
11.	Loose/4 per day	Formed/1 per day	Formed/1 per day
12.	Loose/5 per day	Formed/1 per day	Formed/1 per day
13.	Loose/ 6 per day	Formed/2 per day	Formed/1 per day
14.	Loose/ 8 per day	Formed 2 per day	Formed/1 per day
15.	Loose/4 per day	Formed/1 per day	Formed/1 per day
16.	Loose/ 5 per day	Formed/2 per day	Formed/1 per day
17.	Loose/7 per day	Formed/1 per day	Formed/1 per day
18.	Loose/6 per day	Formed/2 per day	Formed/1 per day
19.	Loose/8 per day	Formed/1 per day	Formed/2 per day
20.	Loose/4 per day	Formed/1 per day	Formed/1 per day

[†]10th day of treatment. [‡]30 days after stopping treatment

Study outcome measures (primary) – probiotic group

Serial no. of patients	Pre-treatment stool consistency/frequency	Stool consistency/frequency[†]	Switch-over to oral ranitidine	Stool consistency/frequency[†]	Post-treatment stool consistency/frequency[‡]
1.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
2.	Loose/5 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
3.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
4.	Loose/5 per day	Loose/5 per day	Loose/5 per day	Formed/1 per day	Formed/1 per day
5.	Loose/6 per day	Loose/6 per day	Loose/6 per day	Formed/2 per day	Formed/1 per day
6.	Loose/8 per day	Loose/5 per day	Loose/5 per day	Formed/1 per day	Formed/1 per day
7.	Loose/4 per day	Loose/3 per day	Loose/3 per day	Formed/1 per day	Formed/1 per day
8.	Loose/6 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
9.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
10.	Loose/7 per day	Loose/5 per day	Loose/5 per day	Formed/2 per day	Formed/1 per day

[†]10th day of treatment. [‡]30 days after stopping treatment with oral ranitidine

Study outcome measures (primary) - placebo (vitamin C) group

Serial no. of patients	Pre-treatment stool consistency/frequency	Stool consistency/frequency[†]	Switch-over to oral ranitidine	Stool consistency/frequency[†]	Post-treatment stool consistency/frequency[‡]
1.	Loose/6 per day	Loose/6 per day	Loose/6 per day	Formed/1 per day	Formed/2 per day
2.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
3.	Loose/6 per day	Loose/5 per day	Loose/5 per day	Formed/2 per day	Formed/1 per day
4.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
5.	Loose/5 per day	Loose/5 per day	Loose/5 per day	Formed/2 per day	Formed/1 per day
6.	Loose/6 per day	Loose/6 per day	Loose/6 per day	Formed/1 per day	Formed/1 per day
7.	Loose/7 per day	Loose/6 per day	Loose/6 per day	Formed/1 per day	Formed/2 per day
8.	Loose/6 per day	Loose/6 per day	Loose/6 per day	Formed/2 per day	Formed/1 per day
9	Loose/5 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day
10.	Loose/4 per day	Loose/4 per day	Loose/4 per day	Formed/1 per day	Formed/1 per day

[†]10th day of treatment. [‡]30 days after stopping treatment with oral ranitidine

Adverse Events

There were no adverse events associated with this trial